دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Mid-Term Outcomes Following Percutaneous Pulmonary Valve Implantation Using the “Folded Melody Valve” Technique
Zakaria Jalal, Est?baliz Valdeolmillos, Sophie Malekzadeh-Milani, Andreas Eicken, Stanimir Georgiev, Michael Hofbeck, Ludger Sieverding, Marc Gewillig, Caroline Ovaert, Helene Bouvaist, Xavier Pillois, Jean-Benoit Thambo, Younes Boudjemline
doi : 10.1161/CIRCINTERVENTIONS.120.009707
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e009707
The folded valve is a manual shortening of the Melody device, which has been validated as a valuable therapeutic option for the management of dysfunctional right ventricular outflow tracts needing a short valved stent. In this article, we aimed to evaluate, in a multicenter cohort, the mid-term outcomes of patients in whom a percutaneous pulmonary valve implantation was performed using the folded valve technique.
Acute and Short-Term Outcomes of Percutaneous Transcatheter Mitral Valve Replacement in Children
Nicola Maschietto, Ashwin Prakash, Pedro del Nido, Diego Porras
doi : 10.1161/CIRCINTERVENTIONS.120.009996
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e009996
Despite the improvement of surgical techniques for mitral valve (MV) repair in children, mitral valve replacement (MVR) is sometimes still necessary. MVR and redo-MVR continue to be burdened by early postoperative mortality and long-term morbidity with only about 75% of these patients being alive or transplant-free 10 years after the initial MVR. Although transcatheter MVR (TMVR) is a well-established intervention in high surgical risk adults, only a few pediatric valve-in-valve case reports have been published. The purpose of this study was to describe our initial experience with the off-label use of the Sapien S3 valve for TMVR in a highly selected pediatric patient population.
Left Ventricular Ejection Fraction 1 Year After Acute Myocardial Infarction Identifies the Benefits of the Long-Term Use of ?-Blockers
Chan Soon Park, Han-Mo Yang, You-Jeong Ki, Jeehoon Kang, Jung-Kyu Han, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Chong-Jin Kim, Myeong Chan Cho, Young Jo Kim, Shung-Chull Chae, Myung Ho Jeong, Hyo-Soo Kim and on behalf of the KAMIR-NIH Registry
doi : 10.1161/CIRCINTERVENTIONS.120.010159
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e010159
?-Blockers can improve prognosis after acute myocardial infarction. However, it remains unclear how long ?-blockers should be prescribed.
The Art of Prescribing ?-Blockers After Myocardial Infarction
Liyew Desta, Sergio Raposeiras-Roubin, Borja Ibanez
doi : 10.1161/CIRCINTERVENTIONS.121.010720
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e010720
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype
Daniel M.F. Claassens, Thomas O. Bergmeijer, Gerrit J.A. Vos, Renicus S. Hermanides, Arnoud W.J. van ’t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, Richard M. Tjon Joe Gin, Folkert W. Asselbergs, Arend Mosterd, Jean-Paul R. Herrman, Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder, Bakhtawar K. Mahmoodi, Vera H.M. Deneer, Jurriën M. ten Berg
doi : 10.1161/CIRCINTERVENTIONS.120.009434
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e009434
Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with myocardial infarction. However, the POPular Genetics trial (Patient Outcome After Primary Percutaneous Coronary Intervention [PCI]) showed that in patients with primary PCI, a CYP2C19 genotype–guided strategy was associated with a lower bleeding risk without increasing thrombotic risk, compared with routine ticagrelor/prasugrel treatment. Nevertheless, optimal P2Y12 inhibitor treatment in specific CYP2C19 genetic subgroups is still a subject of debate.
Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement
Howard M. Julien, Amanda Stebbins, Sreekanth Vemulapalli, Ashwin S. Nathan, Nwamaka D. Eneanya, Peter Groeneveld, Paul N. Fiorilli, Howard C. Herrmann, Wilson Y. Szeto, Nimesh D. Desai, Saif Anwaruddin, Amit Vora, Binita Shah, Vivian G. Ng, Dharam J. Kumbhani, Jay Giri
doi : 10.1161/CIRCINTERVENTIONS.120.010032
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e010032
Reported rates of acute kidney injury (AKI) after transcatheter aortic valve replacement in small observational studies vary widely.
Reducing Acute Kidney Injury After Transcatheter Aortic Valve Replacement
Ran Kornowski, Gilbert H.L. Tang
doi : 10.1161/CIRCINTERVENTIONS.121.010718
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e010718
Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial
Zachary M. Gertz, Howard C. Herrmann, D. Scott Lim, Saibal Kar, Samir R. Kapadia, Grant W. Reed, Rishi Puri, Amar Krishnaswamy, Bernard J. Gersh, Neil J. Weissman, Federico M. Asch, Paul A. Grayburn, Ioanna Kosmidou, Bj?rn Redfors, Zixuan Zhang, William T. Abraham, JoAnn Lindenfeld, Gregg W. Stone, Michael J. Mack
doi : 10.1161/CIRCINTERVENTIONS.120.010300
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e010300
Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip.
Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
Matthew W. Sherwood, Aakriti Gupta, Sreekanth Vemulapalli, Zhuokai Li, Jonathan Piccini, J. Kevin Harrison, David Dai, Amit N. Vora, Michael J. Mack, David R. Holmes, John S. Rumsfeld, David J. Cohen, Vinod H. Thourani, Ajay J. Kirtane, Eric D. Peterson
doi : 10.1161/CIRCINTERVENTIONS.120.009963
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e009963
Optimal antithrombotic management of patients with preexisting atrial fibrillation undergoing transcatheter aortic valve replacement is challenging given the need to balance the risk of bleeding and thromboembolism. We aimed to examine variation in care and association of antithrombotic therapies with 1-year outcomes of stroke, bleeding, and mortality in patients undergoing transcatheter aortic valve replacement with concomitant atrial fibrillation in the United States.
Leaps and Gaps in Transcatheter Aortic Valve Replacement Management
Mirvat Alasnag, Gerald V. Naccarelli
doi : 10.1161/CIRCINTERVENTIONS.121.010719
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e010719
Surgical Explantation of Transcatheter Aortic Valve Bioprostheses
Alexander A. Brescia, G. Michael Deeb, Stephane Leung Wai Sang, Daizo Tanaka, P. Michael Grossman, Devraj Sukul, Chang He, Patricia F. Theurer, Melissa Clark, Francis L. Shannon, Stanley J. Chetcuti, Shinichi Fukuhara and on behalf of the Michigan Society of Thoracic and Cardiovascular Surgeons and the Blue Cross Blue Shield of Michigan Cardiovascular Consortium
doi : 10.1161/CIRCINTERVENTIONS.120.009927
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e009927
Despite the rapid adoption of transcatheter aortic valve replacement (TAVR) since its initial approval in 2011, the frequency and outcomes of surgical explantation of TAVR devices (TAVR-explant) is poorly understood.
Pregnancy in the Cardiac Catheterization Laboratory
Amy E. Cheney, Logan L. Vincent, James M. McCabe, Kathleen E. Kearney
doi : 10.1161/CIRCINTERVENTIONS.120.009636
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e009636
Concerns over radiation exposure are ubiquitous to all interventional cardiologists; however, fear of exposure during childbearing years disproportionately deters women from entering the field. This review summarizes the available data on occupational radiation exposure during pregnancy with an emphasis on radiation quantification, the impact of exposure at various stages of fetal development, societal recommendations for safe levels of exposure during gestation, threshold levels necessary to induce fetal harm, and safe practices for the pregnant interventionalist. Reconciling the available information, we conclude that pregnancy in the cardiac catheterization laboratory is both safe and feasible. This review also highlights new technologies that may augment standard radiation safety techniques and are of particular interest to the pregnant interventional cardiologist. Finally, we propose steps to improve female representation in this field, underscoring the importance of a sex-balanced workforce.
Novel Electrosurgical Bailout Technique for Acute Left Main Occlusion Post Redo–Transcatheter Aortic Valve Replacement in a Surgical Bioprosthesis
Vinayak Nagaraja, Amar Krishnaswamy, Grant Reed, James Yun, Samir R. Kapadia
doi : 10.1161/CIRCINTERVENTIONS.120.010466
Circulation: Cardiovascular Interventions. 2021 | Volume 14, Issue 4: e010466
